Safety and efficacy of daptomycin for the treatment of hospitalized adult patients in Taiwan with severe staphylococcal infections
Chung-Chih Lai, Wang-Huei Sheng, Jann-Tay Wang, Chun-Hsin Liao, Mao-Wang Ho, Chwen-Je Chen, Der-Li Chen, Ming-Uen Chou, Chien-Ming Lee, Yee-Chun Lin, Ming-Ye Pong, Shan-Chwen Chang
Received: May 19, 2010 Revised: September 9, 2010 Accepted: October 20, 2010
Shan-Chwen Chang, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
Corresponding author. Division of Infectious Diseases, Department of Internal Medicine, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei 100, Taiwan.
Background and purpose:
The safety and efficacy of treating serious infections caused by Staphylococcus aureus with daptomycin in a Taiwanese population were studied.
A retrospective, multicenter study was performed in Taiwan between December 2007 and June 2009. This study included adult hospitalized patients who had received intravenous daptomycin therapy for infections caused by S aureus. All patients were followed until discharge from the hospital or death.
A total of 52 patients (males, n=44; median age: 62 years) were evaluated. Infections included complicated skin and soft-tissue infections (n=14), catheter-related bacteremia (n=14), osteomyelitis and septic arthritis (n=12), endovascular infections and endocarditis (n=11), and urinary tract infections (n=1). Overall, 47 (90.4%) patients were successfully treated and their clinical symptoms were resolved. Adverse effects related to daptomycin were detected in nine patients, but none were required to discontinue daptomycin.
The results support daptomycin as an effective and safe treatment for staphylococcal infections in Taiwanese populations.
Daptomycin, Methicillin-resistant Staphylococcus aureus, Serious infection